EU Clinical Trials Register

Loading...
EU Clinical Trials Register Home & Search

Joining a trial

Contacts

Help

About

Clinical trials The European Union Clinical Trials Register allows you to search for protocol and results information on: interventional clinical trials that are conducted in the European Union (EU) and the European Economic Area (EEA); clinical trials conducted outside the EU / EEA that are linked to European paediatric-medicine development. Learn more about the EU Clinical Trials Register including the source of the information and the legal basis. The EU Clinical Trials Register currently displays 32083 clinical trials with a EudraCT protocol, of which 5170 are clinical trials conducted with subjects less than 18 years old. The register also displays information on 18700 older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).



X

Please enter search term...

Search

Examples: Cancer AND drug name. Pneumonia AND sponsor name. How to search [pdf]

Advanced Search: Search tools

< Back to search results Summary EudraCT Number:

2016-002000-31

Sponsor's Protocol Code Number:

FSJD-ISON-2016

National Competent Authority:

Spain - AEMPS

Clinical Trial Type:

EEA CTA

Trial Status:

Ongoing

Date on which this record was first entered in the EudraCT database:

2016-08-05

Trial results Index A. PROTOCOL INFORMATION B. SPONSOR INFORMATION C. APPLICANT IDENTIFICATION D. IMP IDENTIFICATION D.8 INFORMATION ON PLACEBO E. GENERAL INFORMATION ON THE TRIAL F. POPULATION OF TRIAL SUBJECTS G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED P. END OF TRIAL A. Protocol Information A.1

Member State Concerned

Spain - AEMPS

A.2

EudraCT number

2016-002000-31

A.3

Full title of the trial

Open clinical trial phase IIa to study the isoniazid suspension absoption of 10mg/ml for the tuberculosis infection treatment in patients under the age of 6 Ensayo clínico abierto fase IIa de estudio de la absorción de la suspensión de isoniazida a 10 mg/ml para el tratamiento de la infección tuberculosa en pacientes menores de 6 años

A.3.1

Title of the trial for lay people, in easily understood, i.e. nonOpen clinical trial phase IIa to study the isoniazid suspension absoption for the tuberculous infection treatment in patients under technical, language the age of 6 Ensayo clínico abierto fase IIa de estudio de la absorción de la isoniazida para el tratamiento de la infección tuberculosa en pacientes menores de 6 años

A.4.1

Sponsor's protocol code number

FSJD-ISON-2016

A.7

Trial is part of a Paediatric Investigation Plan

No

A.8

EMA Decision number of Paediatric Investigation Plan

B. Sponsor Information B.Sponsor: 1 B.1.1

Name of Sponsor

FUNDACIÓ SANT JOAN DE DÉU

B.1.3.4

Country

Spain

B.3.1 and B.3.2

Status of the sponsor

Non-Commercial

B.4 Source(s) of Monetary or Material Support for the clinical trial: B.4.1

Name of organisation providing support

Ministerio de Sanidad y Política Social

B.4.2

Country

Spain

B.5 Contact point designated by the sponsor for further information on the trial B.5.1

Name of organisation

SERMES-CRO

B.5.2

Functional name of contact point

Unidad de Puesta en Marcha

B.5.3

Address:

B.5.3.1

Street Address

C/ Rufino González 14 2º Dcha

B.5.3.2

Town/ city

Madrid

B.5.3.3

Post code

28037

B.5.3.4

Country

Spain

B.5.4

Telephone number

+3491375 69 30

B.5.5

Fax number

+3491754 27 21

B.5.6

E-mail

[email protected]

D. IMP Identification D.IMP: 1 D.1.2 and IMP Role D.1.3

Test

D.2

Status of the IMP to be used in the clinical trial

D.2.1

IMP to be used in the trial has a marketing authorisation

Yes

D.2.1.1.1

Trade name

Isoniazid Syrup USP

D.2.1.1.2

Name of the Marketing Authorisation holder

Pharmascience INC

D.2.1.2

Country which granted the Marketing Authorisation

Canada

D.2.5

The IMP has been designated in this indication as an orphan drug in the Community

No

D.2.5.1

Orphan drug designation number

D.3 Description of the IMP D.3.4

Pharmaceutical form

Syrup

D.3.4.1

Specific paediatric formulation

No

D.3.7

Routes of administration for this IMP

Oral use

D.3.8 to D.3.10 IMP Identification Details (Active Substances) D.3.8

INN - Proposed INN

ISONIAZID

D.3.9.1

CAS number

54-85-3

D.3.9.4

EV Substance Code

SUB08326MIG

D.3.10

Strength

D.3.10.1

Concentration unit

mg/ml milligram(s)/millilitre

D.3.10.2

Concentration type

equal

D.3.10.3

Concentration number

10

D.3.11 The IMP contains an: D.3.11.1

Active substance of chemical origin

Yes

D.3.11.2

Active substance of biological/ biotechnological origin (other No than Advanced Therapy IMP (ATIMP) The IMP is a:

D.3.11.3

Advanced Therapy IMP (ATIMP)

No

D.3.11.3.1 Somatic cell therapy medicinal product

No

D.3.11.3.2 Gene therapy medical product

No

D.3.11.3.3 Tissue Engineered Product

No

D.3.11.3.4 Combination ATIMP (i.e. one involving a medical device)

No

D.3.11.3.5 Committee on Advanced therapies (CAT) has issued a classification for this product

No

D.3.11.4

Combination product that includes a device, but does not involve an Advanced Therapy

No

D.3.11.5

Radiopharmaceutical medicinal product

No

D.3.11.6

Immunological medicinal product (such as vaccine, allergen, No immune serum)

D.3.11.7

Plasma derived medicinal product

No

D.3.11.8

Extractive medicinal product

No

D.3.11.9

Recombinant medicinal product

No

D.3.11.10 Medicinal product containing genetically modified organisms No D.3.11.11 Herbal medicinal product

No

D.3.11.12 Homeopathic medicinal product

No

D.3.11.13 Another type of medicinal product

No

D.8 Information on Placebo E. General Information on the Trial E.1 Medical condition or disease under investigation E.1.1

Medical condition(s) being investigated

tuberculosis infection in patients under the age of 6 Infección tuberculosa en pacientes menores de 6 años

E.1.1.1

Medical condition in easily understood language

tuberculosis infection in patients under the age of 6 Infección tuberculosa en pacientes menores de 6 años

E.1.1.2

Therapeutic area

Diseases [C] - Bacterial Infections and Mycoses [C01]

MedDRA Classification E.1.3

Condition being studied is a rare disease

No

E.2 Objective of the trial E.2.1

Main objective of the trial

Isoniazid maximum concentration description in serum of patients under the age of 6 in treatment with a unique oral daily dose of study drug 10mg/Kg for primary o secundary chemoprophylaxis of latent tuberculosis infection or tuberculosis disease treatment. Describir la concentración máxima de isoniazida en suero en una muestra de pacientes menores de 6 años tratados con el fármaco en estudio a una dosis única oral diaria de 10 mg por kg de peso para la quimioprofilaxis primaria o secundaria de la infección tuberculosa latente o el tratamiento de la enfermedad tuberculosa.

E.2.2

Secondary objectives of the trial

- Describe other pharmacokinetic parameters (are under the curve, time to the maximum concentration), after the isoniazid administration in a unique oral daily dose of 10mg/kg in the study population and the equivalence between the two groups of patients: baby from 1 month to 2 years; and preschoolers, from 2 to 6 years of life. - Study the influence of other factors in the pharmacokinetics parameters studied: gender, nutritional state, treatment indication (primary or secundary chemoprophylaxis of the latent tuberculosis infection or tuberculosis disease treatment), acetylator NAT2 genotype and coadministration of other tuberculostatic drugs. - Treatment security. - Describir otros parámetros farmacocinéticos (área bajo la curva, tiempo a la concentración máxima), tras la administración de isoniazida en una dosis única oral diaria de 10 mg por kg de peso en la población en estudio, y su equivalencia entre los dos grupos de pacientes: lactantes, de 1 mes a 2 años de vida; y prescolares, de 2 a 6 años de vida. - Estudiar la influencia de otros factores en los parámetros farmacocinéticos estudiados: género, estado nutricional, indicación de tratamiento (quimioprofilaxis primaria o secundaria de la infección tuberculosa latente o tratamiento de la enfermedad tuberculosa), genotipo acetilador NAT2 y co-administración de otros fármacos tuberculostáticos. - Seguridad del tratamiento.

E.2.3

Trial contains a sub-study

E.3

Principal inclusion criteria

No - Patients between > or = 29 days and < or = 6 years old. - Patients who require primary or secundary chemoprophylaxis, or treatment for the tuberculosis infection with isoniazid in monotherapy or together other anti-tuberculosis drugs. - Informed consent signed by parents and tutors. - Pacientes entre > o = 29 días y < o = 6 años de vida. - Pacientes que precisen quimioprofilaxis primaria o secundaria, o tratamiento para la infección tuberculosa con isoniazida, en monoterapia o junto a otros fármacos anti-tuberculosos. - Formulario de consentimiento informado firmado por los padres o tutores.

E.4

Principal exclusion criteria

- Any infection disease, hepatic or renal of base susceptible to alter the isoniazid metabolism (i.e. VIH infection or hepatotropos virus). - Treatment necesity with other drugs liable to modify the isoniazid metabolism (i.e. antiepileptic, antiretroviral, etc.). - Study basal hepatic function alteration, defined with a elevation in the alanine aminotransferases levels two or three times the normality higher level, it is 40 UI/L per 2: values > or 80UI/L. - Cualquier enfermedad infecciosa, hepática o renal de base susceptible de alterar el metabolismo de la isoniazida (ej. infección por VIH o virus hepatotropos). - Necesidad de tratamiento con otros fármacos susceptibles de alterar el metabolismo de la isoniazida (ej. antiepilépticos, antirretrovirales, etc.). - Alteración de la función hepática en el estudio basal, definida por una elevación de los niveles de alanino aminotransferasa (ALT) dos o más veces el valor superior de la normalidad, o sea, 40 UI/L por 2: valores > o = 80 UI/L.

E.5 End points E.5.1

Primary end point(s)

Maximum concentration (Cmax) in serum of isoniazid (quantitative variable, in mg/L) Concentración máxima (Cmax) en suero de isoniazida (variable cuantitativa, en mg/L).

E.5.1.1

Timepoint(s) of evaluation of this end point

Patients in monoterapy:1 or 2 hours post-dosis, 3 or 4 hours post-dose, 6 or 8 hours post-dosis. In combined treatment with other drugs anti-tuberculose : Pre-dose, 1 or 2 hours post-dose, 3 or 4 hours post-dose, 6 or 8 hours post-dose and 10 or 12 hours post-dose Pacientes en monoterapia: 1 o 2 horas post-dosis, 3 o 4 horas post-dosis, 6 o 8 horas post-dosis. En tratamiento combinado con otros fármacos anti-tuberculosos: Pre-dosis, 1 o 2 horas post-dosis, 3 o 4 horas post-dosis, 6 o 8 horas post-dosis y 10 o 12 horas post-dosis.

E.5.2

Secondary end point(s)

- Time to the maximum concentration in serum of isoniazid (quantitative variable, in hours). - Minimum concentration in serum of isoniazid (quantitative variable, in mg/L). - Area under the curve of isoniazid concentration in serum (quantitative variable, in mg h/L). From time 0 to 6h (AUC6) and time from 0 to 24h (AUC24) in a posological interval. - Plasmatic clearance of isoniazid (quantitative variable, in L/h) - Apparent distribution volume of isoniazid ( quantitative variable, in liters). - Acetylator genotype (qualitative variable): quick homozygote acetylator, slow homozygote acetylator, or intermediate acetylator. - In patients with tuberculosis disease: disease type (intrathoracic or extratoracic; dichotomic variable) and concomitant treatments with other tuberculostatic drugs (yes/no; dichotomic variable). - Malnutrition (yes/no, dichotomic variable). Defined with weight and/or body mass index lower than -2DS according to the Spanish standar. - Gender, gestational state and weight in the moment of birth, indication about the treatment with isoniazid (primary or secondary chemoprophylaxis of ITL, or tuberculosis disease treatment); age, weight and total daily dose of isoniazid and basal levels of alanine aminotransferase (ALT-UI/mL) to the initial treatment indication with isoniazid; adherence and adverse events to the treatment with isoniazid. - Tiempo a la concentración máxima (tmax) en suero de isoniazida (variable cuantitativa, en horas). - Concentración mínima (Cmin) en suero de isoniazida (variable cuantitativa, en mg/L). - Área bajo la curva (AUC) de concentración de la isoniazida en suero (variable cuantitativa, en mg h/L). De tiempo 0 a 6h (AUC6) y de tiempo 0 a 24h (AUC24) en un intervalo posológico. - Aclaramiento plasmático (CL) de isoniazida (variable cuantitativa, en L/h). - Volumen aparente de distribución (Vd) de isoniazida (variable cuantitativa, en litros). - Genotipo acetilador (variable cualitativa): acetilador rápido homozígoto (RR), acetilador lento homozígoto (LL), o acetilador intermedio (RL). - En los pacientes con enfermedad tuberculosa: tipo de enfermedad (intratorácica o extratorácica; variable dicotómica) y tratamiento concomitante con otros fármacos tuberculostáticos (sí/no; variable dicotómica). - Desnutrición (sí/no, variable dicotómica). Definida por un peso y/o índice de masa corporal inferior a -2 DS de acuerdo a los estándares españoles. - Género, estado gestacional y peso al nacimiento, indicación de tratamiento con isoniazida (quimioprofilaxis primaria o secundaria de la ITL, o tratamiento de la enfermedad tuberculosa); edad, peso y dosis total diaria de isoniazida, y niveles basales de alanina aminotransferasa (ALT - UI/mL) a la indicación inicial del tratamiento con isoniazida; adherencia y efectos adversos al tratamiento con isoniazida.

E.5.2.1

Timepoint(s) of evaluation of this end point

Patients in monotherapy: 1 or 2 hours post-dose, 3 or 4 hours post-dose, 6 or 8 hours post-dose. In combinate treatment with other drugs anti-TB: Pre-dose, 1 or 2 hours post-dose,3 or 4 hours post-dose, 6 or 8 hours post-dose and 10 or 12 hours post-dose. Pacientes en monoterapia: 1 o 2 horas post-dosis, 3 o 4 horas post-dosis, 6 o 8 horas post-dosis. En tratamiento combinado con otros fármacos anti-TB: Pre-dosis, 1 o 2 horas post-dosis, 3 o 4 horas post-dosis, 6 o 8 horas postdosis y 10 o 12 horas post-dosis.

E.6 and E.7 Scope of the trial E.6

Scope of the trial

E.6.1

Diagnosis

No

E.6.2

Prophylaxis

No

E.6.3

Therapy

No

E.6.4

Safety

Yes

E.6.5

Efficacy

No

E.6.6

Pharmacokinetic

Yes

E.6.7

Pharmacodynamic

No

E.6.8

Bioequivalence

No

E.6.9

Dose response

No

E.6.10

Pharmacogenetic

No

E.6.11

Pharmacogenomic

No

E.6.12

Pharmacoeconomic

No

E.6.13

Others

No

E.7

Trial type and phase

E.7.1

Human pharmacology (Phase I)

No

E.7.1.1

First administration to humans

No

E.7.1.2

Bioequivalence study

No

E.7.1.3

Other

No

E.7.1.3.1 Other trial type description E.7.2

Therapeutic exploratory (Phase II)

Yes

E.7.3

Therapeutic confirmatory (Phase III)

No

E.7.4

Therapeutic use (Phase IV)

No

E.8 Design of the trial E.8.1

Controlled

No

E.8.1.1

Randomised

No

E.8.1.2

Open

Yes

E.8.1.3

Single blind

No

E.8.1.4

Double blind

No

E.8.1.5

Parallel group

No

E.8.1.6

Cross over

No

E.8.1.7

Other

No

E.8.2

Comparator of controlled trial

E.8.2.1

Other medicinal product(s)

No

E.8.2.2

Placebo

No

E.8.2.3

Other

No

E.8.3

The trial involves single site in the Member State concerned Yes

E.8.4

The trial involves multiple sites in the Member State concerned

No

E.8.5

The trial involves multiple Member States

No

E.8.6 Trial involving sites outside the EEA E.8.6.1

Trial being conducted both within and outside the EEA

No

E.8.6.2

Trial being conducted completely outside of the EEA

No

E.8.7

Trial has a data monitoring committee

No

E.8.8

Definition of the end of the trial and justification where it is not the last visit of the last subject undergoing the trial

LVLS LVLS

E.8.9 Initial estimate of the duration of the trial E.8.9.1

In the Member State concerned years

2

E.8.9.1

In the Member State concerned months

0

E.8.9.1

In the Member State concerned days

0

F. Population of Trial Subjects F.1 Age Range F.1.1

Trial has subjects under 18

Yes

F.1.1

Number of subjects for this age range:

44

F.1.1.1

In Utero

No

F.1.1.2

Preterm newborn infants (up to gestational age < 37 weeks) No

F.1.1.3

Newborns (0-27 days)

No

F.1.1.4

Infants and toddlers (28 days-23 months)

Yes

F.1.1.4.1 Number of subjects for this age range:

22

F.1.1.5

Yes

Children (2-11years)

F.1.1.5.1 Number of subjects for this age range:

22

F.1.1.6

Adolescents (12-17 years)

No

F.1.2

Adults (18-64 years)

No

F.1.3

Elderly (>=65 years)

No

F.2 Gender F.2.1

Female

Yes

F.2.2

Male

Yes

F.3 Group of trial subjects F.3.1

Healthy volunteers

No

F.3.2

Patients

Yes

F.3.3

Specific vulnerable populations

Yes

F.3.3.1

Women of childbearing potential not using contraception

No

F.3.3.2

Women of child-bearing potential using contraception

No

F.3.3.3

Pregnant women

No

F.3.3.4

Nursing women

No

F.3.3.5

Emergency situation

No

F.3.3.6

Subjects incapable of giving consent personally

Yes

F.3.3.6.1 Details of subjects incapable of giving consent

Under 18 years old. Menores de edad.

F.3.3.7

Others

No

F.4 Planned number of subjects to be included F.4.1

In the member state

44

F.4.2

For a multinational trial

F.4.2.1

In the EEA

44

F.4.2.2

In the whole clinical trial

44

F.5

Plans for treatment or care after the subject has ended the participation in the trial (if it is different from the expected normal treatment of that condition)

No aplicable No aplica

G. Investigator Networks to be involved in the Trial N. Review by the Competent Authority or Ethics Committee in the country concerned N.

Competent Authority Decision

Authorised

N.

Date of Competent Authority Decision

2016-09-21

N.

Ethics Committee Opinion of the trial application

Favourable

N.

Ethics Committee Opinion: Reason(s) for unfavourable opinion

N.

Date of Ethics Committee Opinion

2016-09-20

P. End of Trial P.

End of Trial Status

Ongoing

EU Clinical Trials Register Service Desk: https://servicedesk.ema.europa.eu European Medicines Agency © 1995-2018 | 30 Churchill Place, Canary Wharf, London E14 5EU

Loading...

EU Clinical Trials Register

EU Clinical Trials Register Home & Search Joining a trial Contacts Help About Clinical trials The European Union Clinical Trials Register allows ...

64KB Sizes 3 Downloads 15 Views

Recommend Documents

EU Clinical Trials Register
Feb 15, 2012 - El objetivo principal del estudio es evaluar si la adición de LABA a la terapia con ICS (FSC) no es infe

EU Clinical Trials Register
Tc-99m DTPA used as reference imaging to evaluate the distribution of other tumor-seeking tracers in tumors associated w

EU Clinical Trials Register
Feb 26, 2015 - Ensayo clínico para evaluar al seguridad de un gel vaginal que contiene estriol 0.005%, en mujeres menop

2 Synopsis - EU Clinical Trials Register
Jun 23, 2009 - repeated biopsy attempts of obtaining endometrial tissue, being indicative of atrophic endometrium; 1 was

Clinical Trials Register
Apr 18, 2005 - Estudio abierto, multicéntrico y aleatorizado sobre la eficacia y seguridad de la reducción de dosis de

2012-004441-32 - Clinical Trials Register
Mar 6, 2013 - Patients diagnosed with gonarthrosis II, III and IV degrees of Kellgren and Lawrence. Pacientes diagnostic

2008-007237-47 - Clinical Trials Register
Perioperative physostigmine prophylaxis for liver resection patients at risk for delirium and postoperative cognitive dy

2012-004082-41 - Clinical Trials Register
Mar 6, 2013 - D.2.1.1.1, Trade name, Anticholium. D.2.1.1.2, Name of the Marketing Authorisation holder, Dr. F. Köhler

2009-017405-11 - Clinical Trials Register
May 6, 2010 - Regeneración del cartílago articular en gonartrosis de IIº, IIIº y IVº grados mediante infiltración

Randomization in Clinical Trials
Randomization in Clinical Trials. Version 1.0 May 2011. 1. Simple Randomization. 2. Block randomization. 3. Minimization